EXCLUSIVE: Field Trip’s Co-founder and Executive Chairman Ronan Levy on Investor Opportunities Following Nasdaq Listing
Field Trip will join the Nasdaq exchange on 29 July and become the first psychedelic company to list on Nasdaq’s Global Select Market, having met the stringent financial requirements for the stock exchange’s top tier.
The eagerly anticipated uplisting is the latest in a series of significant company announcements. In February, Field Trip signed a bought deal with investment bank Bloom Burton Securities, and in March raised US$95m in a single funding round. The organisation’s financiers are predominantly investment banks and hedge funds, but what does the support of institutional investors mean for the recognition and regulation of psychedelic medicine?Read More